Published in final edited form as:

J Ind Microbiol Biotechnol. 2010 June ; 37(6): 559–566. doi:10.1007/s10295-010-0701-1.

Genetic factors that influence moenomycin production in streptomycetes

Roman Makitrynsky¹, Yuriy Rebets², Bohdan Ostash¹, Nestor Zaburannyi¹, Mariia Rabyk¹, Suzanne Walker², and Victor Fedorenko¹

Suzanne Walker: suzanne_walker@hms.harvard.edu

¹Department of Genetics and Biotechnology, Ivan Franko National University of L'viv, L'viv, Ukraine

²Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, USA

Abstract

Moenomycin, a natural phosphoglycolipid product that has long history of use in animal nutrition, is currently considered attractive starting point for the development of novel antibiotics. We recently reconstituted the biosynthesis of this natural product in a heterologous host, *Streptomyces lividans* TK24, but production levels were too low to be useful. We have examined several other streptomycetes strains as hosts and have also explored the overexpression of two pleiotropic regulatory genes, *afsS* and *relA*, on moenomycin production. A moenomycin-resistant derivative of *S. albus* J1074 was found to give the highest titers of moenomycin and production was improved by overexpressing *relA*. Partial duplication of *moe* cluster 1 in *S. ghanaensis* also increased average moenomycin production. The results reported here suggest that rational manipulations of global regulators combined with increased *moe* gene dosage could be a useful for improvement of moenomycin biosynthesis.

Keywords

Streptomyces; moenomycin; regulation; heterologous hosts; global regulators

Introduction

Significant effort has been put into understanding the biology of secondary metabolism of actinomycetes in order to accelerate and simplify the generation of industrial overproducers from typically low producing wild type strains [3]. The regulation of antibiotic production is a complex multigene trait where genetic circuits of different rank, environmental and intracellular cues are intricately combined to tune the expression of certain metabolic pathway [4,13]. Although the general architecture of such regulation seems to be conserved across the species, its effects on production of a given molecule can not always be predicted and have to be addressed experimentally [7].

We are interested in moenomycin A (MmA; Fig. 1), a phosphoglycolipid antibiotic that inhibits peptidoglycan biosynthesis. For almost four decades MmA has been used as an animal growth promoter without notable rise of MmA-resistant microflora. Now, when chemotherapy of human infections faces serious shortage of efficient drugs, MmA has attracted the attention of both chemists and biologists as a promising model for the development of novel class

antibiotics to treat multidrug resistant pathogens [17,31,33]. Exploiting its promise requires having access to significant quantities of moenomycin intermediates for further modification. We have previously identified the genes for MmA biosynthesis in the producing organism, *S. ghanaensis*, and have shown that a variety of Mms can be successfully expressed in *S. lividans* TK24 [23]. However, low Mm production levels in both the natural producer, *S. ghanaensis*, and the heterologous host call for the development of better Mm-producing strains. Since no apparent regulatory genes were found in the MmA biosynthetic gene (*moe*) cluster [21], and the genetic factors that control its production are not understood, we have examined several different strategies to improve biosynthesis in the model moenomycin-producing strains. Our initial studies, reported below, support the idea that manipulating global antibiotic regulatory genes and gene dosage in suitable strain backgrounds can lead to useful improvements in production levels for other studies.

Materials and methods

Bacterial strains and plasmids

Escherichia coli DH5 α (Life Technologies, Carlsbad, CA, USA) was used for routine subcloning. *E. coli* ET12567 (pUB307) was used to perform intergeneric conjugation from *E. coli* to *Streptomyces* strains. *Bacillus cereus* ATCC19637 was used as a test-culture for antibiotic disc diffusion assays. Commonly used *S. coelicolor* M145, M512, *S. lividans* TK24, 1326 [14] and *S. albus* J1074 [6] strains were tested here as Mm producers. Plasmids pKD46 and pKD4 were a gift from Prof. J. Beckwith (Harvard Medical School, USA); they were used to carry out RedET-mediated gene replacement as described in following paragraph. *Streptomyces* expression vectors pKC1218E, pIJ6902, pSOK101 and cosmid moeno38-1 were described previously [13,21]. *S. coelicolor* *relA* expression construct pIJ6085 was provided by Prof. M. Bibb (JIC, Norwich, UK).

Culture conditions and general methods

Standard genetic techniques for *E. coli* and *Streptomyces* and for DNA manipulations were used as described [14,25]. *Streptomyces* strains were grown in liquid R5A [26] or TSB media [14] for Mm production. *E. coli* and *Bacillus* strains were grown in LB supplemented with appropriate antibiotics. Oatmeal medium [18] was used to obtain spores of streptomycetes and to plate intergeneric matings. Where needed, streptomycete strains were incubated in the presence of antibiotics: kanamycin (50 $\mu\text{g ml}^{-1}$), apramycin (50 $\mu\text{g ml}^{-1}$) or hygromycin (100 $\mu\text{g ml}^{-1}$). T4 DNA ligase and restriction enzymes were used according to the recommendations of suppliers (NEB, Beverly, MA; MBI Fermentas, Burlington, Ontario, Canada). Other DNA manipulations were carried out following standard procedures specified by the manufacturers (NEB; MBI Fermentas; Invitrogen, Carlsbad, CA, USA; Biorad, Hercules, CA, USA).

Moenomycin extraction, purification and quantitative analysis

100-ml flasks with 15 ml of seed medium (TSB) were inoculated with frozen spore suspension (2×10^5 cfu). The flasks were incubated at 28°C for 48 h on a rotary shaker at 180 rpm. 1 ml of the resulting seed broth was used to inoculate the 300-ml flasks with 30 ml of fermentation medium (R5A for heterologous hosts and TSB for *S. ghanaensis* strains). The fermentation was carried out on a rotary shaker at 180 rpm for 5 days at 30°C. The fermented broth was centrifuged at 3,500 rpm for 10 min. The mycelium was washed twice with distilled water. Mm was extracted by stirring the biomass (1 g, wet weight) with 3 ml of methanol for 12 h. The extract was concentrated *in vacuo* and diluted to the final volume of 300 μl . Then it was either directly used for antibiotic disc diffusion assay or purified for LC-MS analysis according to the described procedure [21–23]. For the antibiotic diffusion assay, paper discs ($\varnothing 5\text{mm}$, Whatman, Maidstone, UK) were impregnated with a portion of the extract and dried at 37°C for 1 h. Discs were placed on the plates with 0.7 % soft agar containing *B. cereus* (10^8 cfu).

The plates were incubated at 4°C for 1 h and then at 37°C for 17 h. Relative changes in moenomycin production by various strains were determined with the help of LC-MS as described [23]. For heterologous strains, quantity of compound **2** (Fig. 1) was determined, whereas for *S. ghanaensis* strains Mm productivity is the sum of production of MmA and its intermediate **1** (Fig. 1). Mean values were found from at least four biological repeats and standard deviations (σ) are shown on Fig. 3 and 4. Several control experiments were carried out to ensure that multistep purification and analysis process did not distort the measurements. Samples that contain increasing concentrations of MmA (in 0.003–10 μ M range) were run through LC-MS and shown to give proportional increase in MmA-specific mass-peak area. Pure MmA was used as an internal standard for Mm extracts from heterologous hosts. The only samples that showed essentially identical MmA : **2** ratio upon LC-MS analysis were then taken into account. Under our LC-MS conditions [23], 1 AU of moenomycin productivity corresponds to 1580.6 Da peak area resulted from injection of 100 pM MmA; 10⁵ AU correspond to 10 μ M MmA.

Verification of the strains containing cosmid moeno38-5

Kanamycin- and hygromycin-resistant transconjugants carrying cosmid moeno38-5 were checked for the stability of inheritance of antibiotic resistance phenotype. 200 clones of each transconjugant were checked after three passages under nonselective conditions and all were found to retain the expected phenotype. PCR was employed to prove the presence of moeno38-5 in the chromosomes of streptomycete hosts. For this purpose we used primers *moeO5up* and *moeO5rev* (Table 1S, Electronic Supplemental Materials, ESM) specific for *moeO5* gene and those used to amplify *attR*^{ΔC31} [28], the “right” arm of moeno38-5 integration. The amplicons of expected size (1.3 and 0.6 kb for *moeO5* and *attR*^{ΔC31}, respectively) were amplified from all transconjugants in case of both primer pairs.

Plasmid construction

For *afsS* overexpression—pIJ4112 [11] was treated with PstI and resulting 2.9 kb fragment containing the entire *afsS* and a part of *afsR* genes was cloned into PstI-digested vector pKC1218E [21]. The final construct (pKCafS) contained gene *afsS* under the control of *ermEp*^{*}.

For *moeO5p-neo* fusion—A 1.5-kb DNA fragment carrying the fd terminator, MCS and promoterless neomycin resistance gene *neo* was amplified from pMO9 using primers *terforNheI* and *neorevMfeI* [24], cloned into pGEM T-easy vector (Promega, Madison, WI, USA) to give pGN1. The 515 bp DNA fragment adjacent to *moeO5* gene that includes first 35 bp of the ORF was amplified with primers O5PFHindIII and O5PRXbaI (Table 1S, ESM) from cosmid moeno38-1 [21] and cloned into pSTBlue1 Acceptor vector (Novagen, Whitehouse Station, NJ, USA). The promoter region was retrieved with HindIII-XbaI and cloned into respective sites of pGN1. Obtained plasmid pGNO5P was digested with NheI and MfeI and the *neo* cassette fused to *moeO5p* was cloned into EcoRI/XbaI sites of pOOB5 [21] to give pONO5P. All constructs mentioned in this study were verified by sequencing at the Biopolymer Facility (Harvard Medical School).

For *moeO5p* titration experiments—A 0.5 kb DNA fragment upstream of *moeO5* start codon was amplified with aforementioned primers O5PFHindIII and O5PRXbaI. The resulting amplicon was digested with HindIII and XbaI and cloned into respective sites of high-copy number pIJ101-based vector [14] pSOK101 to give pSOKmoeO5p.

Cosmid moeno38-5—was constructed to ensure that *moe* cluster-flanking 18-kb segment of *S. ghanaensis* chromosome (Fig. 2) does not cause any possible effects on Mm production by heterologous strains. The kanamycin resistance gene from plasmid pKD4 [8] was amplified

with primers 38start-KD4 and moeA5-P3 (Table 1S, ESM). The resulting amplicon was used to replace the *moeA4moeB5* gene pair as well as the entire 18-kb “left arm” of moeno38-1 (Fig. 2) using the described λ Red approach [8]. We did not evict the *kanR* gene region from moeno38-5 because it did not exert any negative effects on MmA production. The replacement of the *moeA5* and *moeB5* genes with *kanR* in moeno38-5 was confirmed via diagnostic PCR (primers P2-KD4 and alsrev1 (Table 1S, ESM). Levels of Mm production by moeno38-5⁺ and moeno38-1⁺ *S. lividans* TK24 transconjugants were identical (data not shown), implying that no regulatory or structural moe genes were present in the deleted 18-kb region.

Semiquantitative RT-PCR

Total RNA samples were isolated after 4 days of *S. albus* growth in R5A according to instructions of manufacturer of RNeasy kit (Qiagen, Valencia, CA). To avoid DNA contamination, samples were treated with RQ1 DNase (Promega). RNA concentration and purity were determined by measuring the ratio of OD₂₆₀/OD₂₈₀, and an equal amount of RNA from each studied strain was used for RT reaction. cDNA was obtained using AMV Reverse Transcriptase (Promega) and random hexanucleotide primers. PCR was performed using Go-Taq DNA polymerase (Promega) and primer pairs specific to *moeO5* and *moeE5* genes (350 bp segments, Table 1S, ESM). As a positive control, the *rrnA* primer pair specific to 16S rRNA of *Streptomyces coelicolor* (380 bp segment) was used. Negative controls were carried out with *rrnA* primers to confirm the absence of contaminating DNA in the RNA preparations. PCR products were analyzed by electrophoresis in 1.2% agarose gel, and band intensity was established by the ImageJ1.36b software (National Institutes of Health, Bethesda, MD, USA).

Screening for global regulators in genomes of *S. ghanaensis* ATCC 14672 and *S. albus* J1074

To assess the presence of pleiotropic regulators of antibiotic production in the genomes of *S. ghanaensis* ATCC 14672 and *S. albus* J1074, draft genomic assemblies of these strains were downloaded from web-site of Broad Institute (http://www.broad.mit.edu/annotation/genome/streptomyces_group/). The Open Read Frame (ORF) prediction was performed by self-training application Glimmer3 [9] with default settings. Protein sequences of 20 known global regulators of *S. coelicolor* A3(2) secondary metabolism were collected from GenBank with subsequent BLAST [1] comparison to the genomes of interest. The list of regulators and other details are given in the ESM. Apart from turning off “low-complexity filtering” in BLAST suite, we have used default values. In few cases manual adjustment of predicted ORFs was needed (i.e. if the sequence alignment extended beyond ORF boundaries with high probability). The identity value in the table is derived from best high-scoring pair (HSP) from BLAST output, not the whole proteins, however in most cases these coincide (or almost coincide). Due to the unfinished status of sequencing projects of both genomes, no data on exact location in the chromosome neither fixed locus tags for the predicted regulators can be presented.

Results

Generation and analysis of novel heterologous hosts for Mm production

Although novel MmA analogs were successfully isolated from recombinant *S. lividans* strains [21,23,33], their low productivity (up to 500 $\mu\text{g L}^{-1}$) is a formidable challenge for purification of large amounts of Mm's needed for various studies. Better heterologous moenomycin producers would significantly facilitate the chemoenzymatic synthesis of novel phosphoglycolipids. Since generation and especially analysis of Mm-producing strains is laborious, a simple method to find the optimal host(s) would be desirable. We reasoned that the efficiency of expression of key gene for MmA production, *moeO5* [23] in different strains could be used to sort them according to ability to produce Mm. The activity of *moeO5* promoter has been established in promoter titration experiments. Particularly, *S. ghanaensis*

pSOKmoeO5p⁺ strain, carrying multiple *moeO5p* copies *in trans*, accumulated significantly smaller amounts of moenomycins in mycelium ($(0.3 \pm 0.1) \times 10^5$ au mg⁻¹ dry biomass) as compared to control strain ($(1.4 \pm 0.2) \times 10^5$ au mg⁻¹ dry biomass). Hence, as-yet-unknown transcriptional activator(s) appear to interact with *moeO5p* and their activity is effectively “diluted” by plasmid-borne *moeO5p*. This result encouraged us to construct pONO5P that carries the transcriptional fusion of *moeO5p* to promoterless kanamycin resistance gene *neo*. As a test case, we compared the kanamycin resistance levels that pONO5P confers to three strains widely used as heterologous hosts, namely *S. coelicolor* M512 ($\Delta actII-ORF4$, $\Delta redD$), *S. lividans* TK24 and *S. albus* J1074. The 10- μ l aliquots containing approx. 2×10^4 cfu of three independent pONO5P⁺ transconjugants of each aforementioned strain were applied to TSB agar plates supplemented with different amounts of kanamycin (1, 2.5, 5, 7.5, 10, 15, 25 and 50 μ g ml⁻¹). Only *S. albus* grew at the highest kanamycin concentration tested (50 μ g ml⁻¹). Good growth of *S. lividans* TK24 was observed on TSB with 25 μ g ml⁻¹ of kanamycin, whereas *S. coelicolor* M512 grew on 2.5 μ g ml⁻¹. No growth of the control. M512, TK24 strains carrying empty vector was observed at the lowest kanamycin concentration tested. In the case of control J1074 strain, a slight growth was observed at 2.5 μ g ml⁻¹ of kanamycin. Next, cosmid moeno38-5 (carrying no additional segments of *S. ghanaensis* genome except for the *moeD5-moeGT3* portion of *moe* cluster 1 (Fig. 2)), was introduced into different strains of *S. albus*, *S. coelicolor* and *S. lividans* J1074 to compare their Mm production level. *S. albus* gave the highest Mm titer, while M512 had the lowest one. There was approximately a 30-fold difference in production levels between J1074 and M512, showing considerable variation between heterologous hosts (Fig. 3). Expression of *moeO5p-neo* construct and Mm production in the strains being tested seem to correlate positively, therefore such reporter system can potentially be used as a tool to screen for optimal strains and conditions for Mm production.

S. coelicolor is naturally resistant to MmA, as are most streptomycetes strains we have examined, but *S. albus* 1074 is sensitive, with a survival rate of 0.001% at 1 μ g mL⁻¹ of MmA (data not shown). Since MmA sensitivity could affect production levels in *S. albus*, we introduced cosmid38-5 into the spontaneous MmA resistant *S. abus* strain R1 (97% survival at 1 μ g mL⁻¹ of MmA; data not shown) and compared growth and Mm accumulation in the R1 and J1074 transconjugants. The resistant strain showed a negligible increase in Mm production. Since MmA is primarily accumulated inside of the cells [23] and its target is located on cell surface, it is conceivable that certain (low) levels of MmA production can be achieved even by streptomycetes very sensitive to exogenously added MmA.

Since cross-regulation of antibiotic production has been previously reported for *S. coelicolor*, we examined whether the heterologous production of Mms could be affected by the expression of actinorhodin (Act) and undecylprodigiosin (Red). The Mm production levels in moeno38-5⁺ *S. coelicolor* M145 (Act⁺ Red⁺) were still low, but were reproducibly higher (three times) than in the Act- and Red-deficient variant moeno38-5⁺ M512 (Fig. 3A). Hence, some of the *act/red* genes or Act/Red themselves have a positive, albeit modest influence on MmA biosynthesis.

We also investigated the influence of a mutation in the *rpsL* gene in *S. lividans* on Mm production levels. *S. lividans* TK24, used as the original heterologous host for Mm production, contains a point mutation (K43R) in the *rpsL* gene encoding ribosomal protein S12. This mutation is reported to enhance antibiotic production in various actinomycetes [27]. To determine the effect of this mutation on Mm production, we compared expression of Mms in *S. lividans* TK24 (*rpsL* mutant) and the parent strain *S. lividans* 1326. Both antibiotic disc diffusion and LC-MS analyses (Fig. 3) showed that 1326 and TK24 accumulated comparable amounts of moenomycins. Hence, the *rpsL* K43R mutation does not significantly affect the level of Mm production.

***In silico* analysis and initial *in vivo* experiments show that certain global regulators may influence Mm production**

The absence of pathway-specific regulatory genes associated with *moe* cluster and its differential expression in various streptomycetes point to the possibility that some global antibiotic biosynthesis regulators govern MmA production. Such regulators are well studied in *S. coelicolor* [19] and we searched for their counterparts in partially sequenced genomes of *S. ghanaensis* and *S. albus* J1074. Our *in silico* analysis showed that both strains possess homologues of transcriptional factors, components of A-factor signaling cascade and other proteins orchestrating secondary metabolism of *S. coelicolor* (Table 2S, ESM). Two *S. coelicolor* genes, *afsS* and *relA*, were chosen as a test case to obtain experimental evidence for their possible role in regulation of MmA production. These genes are known to cause the overproduction of secondary metabolites in *S. coelicolor*, *S. lividans* and *S. avermitilis* [4,11, 15,30]. The exact function of *afsS* gene is unknown [16], while *relA* encodes (p)ppGpp synthetase [29]. Strain *S. albus* R1 moeno38-5⁺ *relA*⁺ showed 2-fold increase in Mm production level compared to *S. albus* R1 moeno38-5⁺ carrying empty vector (Fig. 3). Overexpression of *afsS* gene in *S. albus* R1 moeno38-5⁺ increased Mm production negligibly (1.25-fold; Fig. 3A, B). We introduced the described above regulatory genes into *S. ghanaensis* ATCC14672 and studied their effects on MmA production. Gene *afsS* had not impact on Mm biosynthesis, while *relA*⁺ strain produced roughly 2-fold more Mm than control strain *S. ghanaensis* (pIJ6902) (Fig. 3). Of all combinations tested, *relA* expression in *S. albus* had the biggest positive impact on Mm production, and we investigated this case in more details. Although growth curves of *relA*⁺ and control strains were virtually identical, there is marked increase in specific Mm productivity of *relA*⁺ variant starting from the end of 4th day, which declines slightly on the 6th day. This is paralleled by increased transcription of two key *moe* genes, *moeO5* and *moeE5*, on 4th day of fermentation of 38-5⁺*relA*⁺ strain as judged by semiquantitative RT-PCR (Fig. 5).

Increased *moe* gene dosage influences MmA production by *S. ghanaensis*

Massive amplification of antibiotic biosynthesis genes is often one of the outcomes of empirical strain improvement programs [10,32]. To test whether increased dosage of *moe* genes could be used as a tool to enhance MmA biosynthesis, we integrated cosmid moeno38-5 into *S. ghanaensis* attB^ΔC31 site. The resulting strain thus carries at least two copies of most of *moe* cluster 1 genes. We revealed that introduction of moeno38-5 into *S. ghanaensis* led, on average, to 2-fold increase in Mm production (Fig. 3C).

Discussion

MmA is considered a promising lead to combat vancomycin- and methicillin-resistant pathogens because of high potency, uniqueness of structure and mode of action [12,17]. Better knowledge of the factors that limit Mm production by streptomycetes would certainly help resolve the issue of intrinsically low Mm yields. Here we describe a simple reporter system that may be used to find efficient heterologous host for production of moenomycins. In a test case, screening of several well-studied streptomycetes turned up heterologous host, *S. albus*, that is better than *S. lividans* or *S. coelicolor* in terms of Mm production level and ease of antibiotic purification (because of the fast and dispersed growth and absence of pigmented metabolites). Of note, we revealed a dramatic difference in Mm-producing capacities of several species being tested, highlighting the importance of host-specific genetic factors for antibiotic production. More extensive screening with the help of described reporter system may reveal even better strain.

We also addressed for the first time the possibility of use of heterologous regulatory elements for MmA improvement. As the *relA* expression shows, at least some of the well-known

pleiotropic regulatory genes might exert significant effects on Mm production, probably through direct or indirect modulation of expression of structural *moe* genes. This result encourages further investigations on possible use of *S. coelicolor* global regulators to enhance Mm biosynthesis. Finally, duplication of *moe* cluster segments may increase antibiotic yields. We envision that proper combination of the discovered genetic factors with optimized fermentation media and purification procedures can significantly improve the production of novel moenomycins by recombinant strains. It is not known at the moment, whether positive effects observed in our work (e.g. *relA* expression and *moe* gene dosage) will be additive. Although the results presented here are for model/wild type strains, their application to known industrial strains or other potential heterologous hosts is anticipated to exert similar effects on Mm production.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work is supported by grant Bg-01F from Ministry of Education and science of Ukraine (to V. F.) and NIH grant AI50855 (to S. W.).

References

1. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. *J Mol Biol* 1990;215:403–410. [PubMed: 2231712]
2. Baizman ER, Branstrom AA, Longley CB, Allanson N, Sofia MJ, Gange D, Goldman RC. Antibacterial activity of synthetic analogues based on the disaccharide structure of moenomycin, an inhibitor of bacterial transglycosylase. *Microbiology* 2000;146:3129–3140. [PubMed: 11101671]
3. Baltz RH. Genetic manipulation of antibiotic-producing *Streptomyces*. *Trends Microbiol* 1998;6:76–83. [PubMed: 9507643]
4. Bibb MJ. Regulation of secondary metabolism in streptomycetes. *Curr Opin Microbiol* 2005;8:208–215. [PubMed: 15802254]
5. Champness, W. Actinomycete development, antibiotic production and phylogeny: questions and challenges. In: Brun, YV.; Skimkets, LJ., editors. *Prokaryotic development*. Washington DC: American Society for Microbiology; 2000. p. 11–31.
6. Chater KF, Wilde LC. *Streptomyces albus* G mutants defective in the SalGI restriction-modification system. *J Gen Microbiol* 1980;116:323–334. [PubMed: 6246193]
7. Chen L, Lu Y, Chen J, Zhang W, Shu D, Qin Z, Yang S, Jiang W. Characterization of a negative regulator AveI for avermectin biosynthesis in *Streptomyces avermitilis* NRRL8165. *Appl Microbiol Biotechnol* 2008;80:277–286. [PubMed: 18560830]
8. Datsenko K, Wanner BL. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci USA* 2000;97:6640–6645. [PubMed: 10829079]
9. Delcher AL, Bratke KA, Powers EC, Salzberg SL. Identifying bacterial genes and endosymbiont DNA with Glimmer. *Bioinformatics* 2007;23:673–679. [PubMed: 17237039]
10. Fedorenko V, Golets L, Demydchuk Yu, Kriugel H. Analysis of genome rearrangements in *Streptomyces kanamyceticus* mutants. *Antibiot Khimitoter (Rus)* 1998;43:14–19.
11. Floriano B, Bibb M. *afsR* is a pleiotropic but conditionally required regulatory gene for antibiotic production in *Streptomyces coelicolor* A3(2). *Mol Microbiol* 1996;21:385–396. [PubMed: 8858592]
12. Goldman RC, Gange D. Inhibition of transglycosylation involved in bacterial peptidoglycan synthesis. *Curr Med Chem* 2000;7:801–820. [PubMed: 10828288]
13. Huang J, Shi J, Molle V, Sohlberg B, Weaver D, Bibb MJ, Karoonuthaisiri N, Lih CJ, Kao CM, Buttner MJ, Cohen SN. Cross-regulation among disparate antibiotic biosynthetic pathways of *Streptomyces coelicolor*. *Mol Microbiol* 2005;58:1276–1287. [PubMed: 16313616]

14. Kieser, T.; Bibb, M.; Buttner, MJ.; Chater, KF.; Hopwood, DA. Practical *Streptomyces* genetics. Norwich: John Innes Foundation; 2000.
15. Lee J, Hwang Y, Kim S, Kim E, Choi C. Effect of a global regulatory gene, *afsR2*, from *Streptomyces lividans* on avermectin production in *Streptomyces avermitilis*. J Biosci Bioeng 2000;89:606–608. [PubMed: 16232806]
16. Lian W, Jayapal KP, Charaniya S, Mehra S, Glod F, Kyung YS, Sherman DH, Hu WS. Genome-wide transcriptome analysis reveals that a pleiotropic antibiotic regulator, AfsS, modulates nutritional stress response in *Streptomyces coelicolor* A3(2). BMC Genomics 2008;9:56. [PubMed: 18230178]
17. Lovering AL, de Castro LH, Lim D, Strynadka NC. Structural insight into the transglycosylation step of bacterial cell-wall biosynthesis. Science 2007;315:1402–1405. [PubMed: 17347437]
18. Luzhetskyy AM, Ostash BO, Fedorenko VO. Intergeneric conjugation *Escherichia coli*–*Streptomyces globisporus* 1912 with using of integrative plasmid pSET152 and its derivative. Rus J Genet 2001;37:1340–1347.
19. McKenzie NL, Nodwell JR. Phosphorylated AbsA2 negatively regulates antibiotic production in *Streptomyces coelicolor* through interactions with pathway-specific regulatory gene promoters. J Bacteriol 2007;189:5284–5292. [PubMed: 17513473]
20. Ostash B, Walker S. Bacterial transglycosylase inhibitors. Curr Opin Chem Biol 2005;9:459–466. [PubMed: 16118062]
21. Ostash B, Saghatelian A, Walker S. A streamlined metabolic pathway for the biosynthesis of moenomycin A. Chem Biol 2007;14:257–267. [PubMed: 17379141]
22. Ostash B, Makitrinsky R, Walker S, Fedorenko V. Identification and characterization of *Streptomyces ghanaensis* ATCC14672 integration sites for three actinophage-based plasmids. Plasmid 2009;61:171–175. [PubMed: 19167423]
23. Ostash B, Doud EH, Lin C, Ostash I, Perlstein DL, Fuse S, Wolpert M, Kahne D, Walker S. Complete characterization of seventeen step moenomycin biosynthetic pathway. Biochemistry 2009;48:8830–8841. [PubMed: 19640006]
24. Ostash I, Ostash B, Luzhetskyy A, Bechthold A, Walker S, Fedorenko V. Coordination of export and glycosylation of landomycins in *Streptomyces cyanogenus* S136. FEMS Microbiol Lett 2008;285:195–202. [PubMed: 18537830]
25. Sambrook, J.; Russel, DW. A laboratory manual. 3rd edn.. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001. Molecular cloning.
26. Sánchez C, Butovich IA, Braña AF, Rohr J, Méndez C, Salas JA. The biosynthetic gene cluster for the antitumor rebeccamycin: characterization and generation of indolocarbazole derivatives. Chem Biol 2002;9:519–531. [PubMed: 11983340]
27. Shima J, Hesketh A, Okamoto S, Kawamoto S, Ochi K. Induction of actinorhodin production by *rpsL* (encoding ribosomal protein S12) mutations that confer streptomycin resistance in *Streptomyces lividans* and *Streptomyces coelicolor* A3(2). J Bacteriol 1996;178:7276–7284. [PubMed: 8955413]
28. Stinchi S, Azimonti S, Donadio S, Sosio M. A gene transfer system for glycopeptide producer *Nonomuraea* sp. ATCC39727. FEMS Microbiol Lett 2003;225:53–57. [PubMed: 12900021]
29. Sun J, Hesketh A, Bibb M. Functional analysis of *relA* and *rshA*, two *relA/spoT* homologues of *Streptomyces coelicolor* A3(2). J Bacteriol 2001;183:3488–3498. [PubMed: 11344157]
30. Vogtli M, Chang PC, Cohen SN. *afsR2*: a previously undetected gene encoding a 63-amino-acid protein that stimulates antibiotic production in *Streptomyces lividans*. Mol Microbiol 1994;14:643–653. [PubMed: 7891553]
31. Taylor J, Li X, Oberthür M, Zhu W, Kahne D. The total synthesis of moenomycin A. J Am Chem Soc 2006;128:15084–15085. [PubMed: 17117848]
32. Yanai K, Murakami T, Bibb M. Amplification of the entire kanamycin biosynthetic gene cluster during empirical strain improvement of *Streptomyces kanamyceticus*. Proc Natl Acad Sci USA 2006;103:9661–9666. [PubMed: 16766657]
33. Yuan Y, Fuse S, Ostash B, Sliz P, Kahne D, Walker S. Structural analysis of the contacts anchoring moenomycin to peptidoglycan glycosyltransferases and implications for antibiotic design. ACS Chem Biol 2008;3:429–436. [PubMed: 18642800]

Fig. 1.

Structures of moenomycins relevant to this study. MmA and compound **1** are accumulated by *S. ghanaensis* strains, while the production of compound **2** is directed by cosmids moeno38-5 and moeno38-1 in heterologous hosts [21].

Fig. 2. Genetic constructs used to express the segments of *moe* cluster 1. 18-kb region of cosmid *moeno38-1* along with genes *moeB5moeA5* have been replaced with kanamycin resistance cassette *kan* (marked as grey rectangle).

Fig. 3.

Levels of moenomycin production by various streptomycete strains. **a** *B. cereus* growth inhibition around paper discs saturated with methanol extracts from 100 mg (wet weight) of biomasses of different Mm producers and control strains: *S. albus* J1074 (1), *S. coelicolor* M145 (2), 2 μ g of MmA (3), M512 moeno38-5⁺ (4), M145 moeno38-5⁺ (5), J1074 moeno38-5⁺ (6), R1 moeno38-5⁺ (7), R1 moeno38-5⁺ *afsS*⁺ (8), R1 moeno38-5⁺ *relA*⁺ (9), TK24 (10), TK24 moeno38-5⁺ (11), 1326 moeno38-5⁺ (12), *S. ghanaensis* (13), *S. ghanaensis relA*⁺ (14). **b** Moenomycin productivity of heterologous strains expressing cosmid moeno38-5. Column labels: TK24, 1326 – *rpsL* and wild type strains of *S. lividans*, respectively; M145, M512 – wild type and Act⁺Red⁺ strains of *S. coelicolor*; J1074, R1 – parent and MmA-resistant strains of *S. abus*, respectively; R1afsS and R1relA – R1 strains overexpressing *afsS* and *relA* genes, respectively. **c** Moenomycin productivity of different *S. ghanaensis* strains. Column labels: ghana – wild type (ATCC14672); ghana afsS, ghana relA and ghana 38-5 – *S. ghanaensis* strains overexpressing *afsS*, *relA* and cosmid moeno38-5, respectively. The Mm production values of *relA*-expressing strains and *S. ghanaensis* carrying duplicated *moe* cluster 1 are statistically significant, since they did not overlap with 2 σ range of the control strains.

Fig. 4.

Time course for biomass and Mm accumulation by *S. albus* R1 38-5 strains with and without *relA*. Solid lines biomass production, dashed lines specific Mm productivity, open diamonds R1 38-5 strain, solid rectangles R1 38-5+*relA* strain. The productivity values are statistically significant as mentioned in the Fig. 3 legend.

Fig. 5.

RT-PCR analysis of *moeO5* and *moeE5* transcription in *S. albus* R1 38-5⁺ and R1 38-5⁺ *relA*⁺ strains during Mm production phase (96 h). Lanes: 2, 5 - *rrnA* transcript from parent and *relA*⁺ strain, respectively; 3, 4 - *moeE5* and *moeO5*, respectively, from R1 38-5⁺*relA*⁺; 6, 7 - *moeE5* and *moeO5*, respectively, from R1 38-5⁺; 8 - negative control (*rrnA* amplification from RNA sample in absence of RT); 1 - 1 kb ladder.

Table 1Plasmids and *Streptomyces* strains constructed in this study

Plasmid/Strain	Genotype/description
pON05P	φC31-based vector, <i>moeO5p</i> -driven expression of <i>neo</i>
pSOKmoeO5p	pSOK101 containing 500 bp promoter region of <i>moeO5</i>
pKCafsS	pKC1218E containing <i>S. coelicolor afsS</i> gene under <i>ermEp</i> *
moeno38-5	Contains major portion of <i>moe</i> cluster 1, carries hygromycin and kanamycin resistance markers (Hyg ^r Km ^r)
<i>S. ghanaensis</i> afsS ⁺ , / relA ⁺ / moe38-5 ⁺	<i>S. ghanaensis</i> ATCC14672 carrying pKCafsS or pIJ6805, or moeno38-5, respectively
TK24/1326 moeno38-5 ⁺	<i>S. lividans</i> TK24 or 1326 strain carrying moeno38-5
M145/M512 moeno38-5 ⁺	<i>S. coelicolor</i> M145 or M512 strain carrying moeno38-5
J1074 moeno38-5 ⁺	<i>S. albus</i> J1074 carrying moeno38-5
R1 moeno38-5 ⁺ / relA ⁺ / afsS ⁺	<i>S. albus</i> R1 expressing: moeno38-5 alone / moeno38-5 + <i>afsS</i> (pKCafsS) / moeno38-5 + <i>relA</i> (pIJ6805)

¹ Details on construction of plasmids and strains can be found in Materials and Methods section